Navigation Links
CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
Date:3/24/2008

VIENNA, Va., March 24 /PRNewswire-FirstCall/ -- CMPMedica has expanded SearchMedica.com to include a number of additional vertical search applications for specialist medical conditions. SearchMedica.com was co- developed with Convera Corporation (Nasdaq: CNVR), http://www.convera.com , a leading provider of vertical search services for publishers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071119/NEM050LOGO )

SearchMedica.com has been serving primary health care professionals in North America, the UK, France and Spain, and Psychiatry and Oncology specialists in North America. Since its launch in late 2006, the popularity of the service has risen dramatically and today generates millions of queries per month.

"We are delighted by the very positive reaction from the medical community as well as from our commercial partners," said Phil Callow, Managing Director of SearchMedica. "Based on user surveys and feedback, we've decided to add further disease-focused custom search functionality so that our full range now includes All of Medicine, Cardiovascular, Diabetes/Endocrine, Infectious, Mental/Nervous System, Musculoskeletal, Cancer/Hemic, Pediatric and Respiratory. This extension is part of CMPMedica's ongoing strategy to widen the scope of the service to satisfy the information and workflow requirements of every major medical domain."

SearchMedica.com , which was co-developed with Convera, is an advertising supported Web-based service that connects physicians and other medical professionals to credible, trusted and editorially approved medical Web sites, online journals and other clinical resources.

About CMPMedica

CMPMedica provides information and education to healthcare professionals and patients around the world. It has a unique portfolio of professional media products including newspapers, magazines, drug directories, electronic databases, websites and events.

About SearchMedica.com

SearchMedica.com indexes only authoritative medical information, approved for inclusion by medical editors and a physician editorial board. Medical professionals receive more relevant, smaller sets of search results from SearchMedica.com than from mainstream engines, which contain consumer- oriented, paid testimonials and other types of unreliable information. Since SearchMedica.com is advertiser supported, medical professionals pay nothing to use the specialty search engine. All SearchMedica search results are independent and unbiased. They contain well-known, credible journals, peer- reviewed research, and evidence-based articles written for practicing healthcare professionals. SearchMedica is currently available at http://www.SearchMedica.com.

About Convera(R)

Convera is the leading provider of search as a service for trade publishers and is the vertical search provider of choice for a growing number of specialist publishers around the world. Convera enables publishers to generate additional revenue by creating customized search applications for specialist audiences under their own brand and also manages the vertical search sites of a growing number of specialist publishers. Convera site search, vertical search and lead generation applications can combine publisher proprietary content with an editorially vetted best of the Web for specific professional audiences, providing an authoritative and comprehensive search experience. Many of the world's largest publishers are working with Convera to accelerate their e-publishing strategies, meet growing online revenue goals and build loyal online professional communities.

This release, including any statements from Convera personnel, contains statements about Convera's future expectations, performance, plans, and prospects, as well as assumptions about future events. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, business and economic conditions and trends; the ability to continue funding operating losses; fluctuations in operating results including impacts from reduced corporate IT spending and lengthier sales cycles; continued success in technological advances and development; possible disruption in commercial activities caused by terrorist activity and armed conflict, such as changes in logistics and security arrangements; reduced customer demand relative to expectations; competitive factors; and other risk factors listed from time to time in the company's reports to the Securities and Exchange Commission. Actual results may differ materially from our expectations as the result of these and other important factors relating to Convera's business and product development efforts, which are further described in Convera's filings with the SEC. These filings can be obtained from the SEC's website located at http://www.sec.gov. Any forward-looking statements are based on information available to Convera on the date of this release, and Convera assumes no obligation to update such statements. Convera(R) and the Convera design logo are trademarks of Convera in the United States and other countries.


'/>"/>
SOURCE Convera
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nova Biosource Fuels Expands Senior Executive Team
2. Finesse Solutions Expands by Opening Sales and Service Centers
3. Evotec Expands Collaboration With InterMune
4. Novo Nordisk Expands U.S. Headquarters in New Jersey
5. Tunnell Consulting Expands Biotechnology Expertise
6. Progen Expands Board of Directors
7. BioVascular, Inc. Expands Executive Team
8. United BioSource Expands Regulatory Affairs Capabilities
9. Valensa Expands Astaxanthin Extraction Capacity
10. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
11. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):